Cardiometabolic
Life insurers are moving from pricing metabolic risk to trying to reduce it
At the 2026 LIMRA Annual Conference, insurers and health companies argued that obesity, diabetes and insulin resistance should be treated not only as underwriting risks but as modifiable drivers of mortality, disability and claims.
Heart-healthy eating is becoming a health-system issue, not just a patient choice
As GLP-1 use scales, dermatology is becoming part of obesity care
Europe Is Moving to Ban Red Yeast Rice Monacolins. Can Bergamot Fill the Gap?
Roche’s Nearly $2B Atavistik Bet Goes After Cardiometabolic Targets Other Drugs Struggle to Reach
Obesity Is Costing Europe Beyond the Clinic. A New Report Puts a Price on It
From Patients to Customers: GLP-1 Marketing Is Rewriting Obesity Care
Novo’s €1.165B Bet Targets the Burden of Weekly Injections
The App Wasn’t Enough: Nurse-Led Digital Diabetes Care Linked to Better HbA1c and Adherence
Retatrutide Isn’t Approved. Online, ‘Reta’ Is Already a Weight-Loss Brand
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Cardiometabolic
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases